[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605856":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":37,"centralContacts":45,"locations":30,"responsibleParty":51,"collaborators":55,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":30,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":97,"whyStopped":30,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":30},{"fullName":5,"class":6},"University of Southern California","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"AADvac1 monotherapy","EXPERIMENTAL","Intravenous infusions of donanemab for 6 months, followed by subcutaneous injections of AADvac1 over 24 months (n = 150)",[13],"Drug: AADvac1",{"label":15,"type":10,"description":16,"interventionNames":17},"Combination AADvac1 therapy with donanemab","Intravenous infusions of donanemab for 6 months, combination donanemab and subcutaneous injections of AADvac1 for 6 months, followed by 18 months of AADvac1 injections alone (n = 150)",[13,18],"Drug: Donanemab",{"label":20,"type":21,"description":22,"interventionNames":23},"Donanemab active control","ACTIVE_COMPARATOR","Intravenous infusions of donanemab for 6 months, combination donanemab and AADvac1-matched placebo subcutaneous injections for 6 months, followed by 18 months of AADvac1-matched placebo injections alone (n = 150).",[18],[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","AADvac1","Subcutaneous injection of AADvac1",[9,15],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Donanemab","Active comparator: intravenous infusion of donanemab",[15,20],[36],"Kisunla",[38,42],{"name":39,"affiliation":40,"role":41},"Adam Boxer, MD, PhD","University of California, San Francisco (UCSF), Memory and Aging Center","PRINCIPAL_INVESTIGATOR",{"name":43,"affiliation":44,"role":41},"Keith Johnson, MD","Massachusetts General Hospital (MGH), Harvard Medical School",[46],{"name":47,"role":48,"phone":49,"phoneExt":30,"email":50},"ATP Recruitment and Retention (RER) Team","CONTACT","213-821-0569","adtau-participate@usc.edu",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"SPONSOR_INVESTIGATOR","Paul S. Aisen","Director, ATRI",[56,59,61,63,65,67],{"name":57,"class":58},"Axon Neuroscience SE","INDUSTRY",{"name":60,"class":6},"University of California, San Francisco",{"name":62,"class":6},"Massachusetts General Hospital",{"name":64,"class":6},"Alzheimer's Therapeutic Research Institute",{"name":66,"class":6},"Alzheimer's Clinical Trials Consortium",{"name":68,"class":69},"National Institute on Aging (NIA)","NIH","100605856","phase-2-alzheimers-tau-platform-regimen-a---aadvac1-100605856",false,"NCT07167966","Alzheimer's Tau Platform: Regimen A - AADvac1","Alzheimer's Tau Platform (ATP): Regimen Specific Appendix for AADvac1","ATP","Inclusion Criteria:\n\n* No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT06957418).\n\nExclusion Criteria:\n\n* No additional exclusion criteria beyond the exclusion criteria specified in the Master Protocol (NCT06957418).","ALL","50 Years","80 Years",{"count":82,"type":83},450,"ESTIMATED","INTERVENTIONAL",[86],"PHASE2","The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease.\n\nRegimen A will evaluate the safety and efficacy of AADvac1, alone or in combination with donanemab.",[89,90,91],"Preclinical Alzheimer's Disease","Prodromal Alzheimer's Disease","Alzheimer Disease",[93,94,95,96],"anti-amyloid mAb","monoclonal antibody (mAB)","tau","amyloid","NOT_YET_RECRUITING","2026-03-31",{"date":100,"type":101},"2026-04-06","ACTUAL",{"date":103,"type":83},"2026-06-30",{"date":105,"type":83},"2028-08-31",{"name":53,"class":6}]